Статья
ТЕОРЕТИЧЕСКОЕ ОБОСНОВАНИЕ И ПРАКТИЧЕСКИЕ АСПЕКТЫ ИСПОЛЬЗОВАНИЯ БИВАЛИРУДИНА ПРИ ЧРЕСКОЖНЫХ ВНУТРИКОРОНАРНЫХ ВМЕШАТЕЛЬСТВАХ У БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ
В аналитической статье представлена ключевая информация о механизме действия прямого ингибитора тромбина – бивалирудина. Обсуждаются отличия этого антикоагулянта от нефракционированного и низкомолекулярных гепаринов, фондапаринукса на уровне механизма действия, особенностей фармакокинетики и фармакодинамики. Тезисно изложены основные результаты клинических исследований с бивалирудином и позиции последнего в действующих рекомендательных документах по ведению больных с острым коронарным синдромом. Детально описаны рекомендуемые дозы бивалирудина и практические меры, призванные обеспечить эффективное и безопасное использование препарата.
1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13–20.
2. Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57: 1920–59.
3. Hamm C.W., Bassand J P., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal 2011; 32:2999–3054.
4. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774–782.
5. Budaj A, Eikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009; 30:655–661.
6. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30:1457–1466.
7. Yusuf S, Mehta SR, Chrolavicius S, et al. Efficacy and safety of fondaparinux compared to enoxaparin in 20,078 patients with acute coronary syndromes without ST segment elevation. The OASIS (Organization to Assess Strategies in Acute Ischemic Syndromes)-5 Investigators. N Engl J Med 2006; 354:1464–1476.
8. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276:811–815.
9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330–1335.
10. Gregg W. Stone, M. D., Brent T., et al. ACUITY Study Group. Bivalirudin for Patients with Acute Coronary Syndromes. N Engl J Med 2006; 355: 2203–16.
11. Stone GW, Witzenbichler B, Guagliumi G, et al. for the HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008 May 22; 358 (21):2218–30.
12. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688–698.
13. Montalescot G, Bal-dit-Solier C, Chibedit D, et al. for the ARMADA investigators. ARMADA study: a randomized comparison of enoxaparin, dalteparin and unfractionated heparin on markers of cell activation in patients with unstable angina. Am J Cardiol 2003; 91:925–930.
14. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36:110–114.
15. Montalescot G, Philippe P, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 1998; 98:294–299.
16. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with low molecular weight heparin and with direct thrombin inhibitor. Circulation 1998; 97:251–256.
17. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995 Sep 21; 333 (12):764–9.
18. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001; 142 (6):952–9.
19. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002 May; 143 (5):847–53.
20. Lincoff AM, Bittl JA, Harrington RA, et al. REPLACE 2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE 2 randomized trial. JAMA. 200319; 289 (7):853–63.
21. Gibson CM, Morrow DA, Murphy SA, et al., TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI 30 trial. J Am Coll Cardiol. 2006 Jun 20; 47 (12):2364–73.
22. Stone G. W., Witzenbichler B., Guagliumi G., et al. Heparin plus a glycoprotein IIb/ IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus baremetal stents in acute myocardial infarction (HORIZONS-AMI): final 3 year results from a multicentre, randomised controlled trial. The Lancet 2011; 377:9784, 2193–2204.
23. Kastrati A., Neumann F J., Schulz S. et al. for ISAR-REACT 4 Trial Investigators. Abciximab and Heparin versus Bivalirudin for Non-ST- Elevation Myocardila Infarction. N engl J Med. 2011; 365:1980–9. 24. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531– 8.
24. Wijns W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization. European Heart Journal (2010) 31, 2501–2555.
25. Levine G. N., Bates E.R., Blankenship J. P. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 2011; 58:24, 2550–2583.
26. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009; 54: 2205– 2241.
27. Van De Werf F, Betriu A, Blomstrom-Lundqvist C, et al., Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909–2945.